Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Cognition Therapeutics, Inc. (CGTX) had Consolidated Net Income/Loss of $-6.73M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-6.73M |
|
-- |
|
-- |
|
$13.98M |
|
$-13.98M |
|
$7.25M |
|
$-6.73M |
|
$-6.73M |
|
$-6.73M |
|
$-6.73M |
|
|
Consolidated Net Income/Loss |
$-6.73M |
$-6.73M |
|
$-13.98M |
|
$-13.92M |
|
63.69M |
|
63.69M |
|
$-0.11 |
|
$-0.11 |
|
| Balance Sheet Financials | |
$19.05M |
|
$0.17M |
|
$0.57M |
|
$19.62M |
|
$12.36M |
|
-- |
|
$0.23M |
|
$12.59M |
|
$7.03M |
|
$7.03M |
|
$7.03M |
|
64.96M |
|
| Cash Flow Statement Financials | |
$-15.50M |
|
-- |
|
$2.05M |
|
$25.01M |
|
$11.56M |
|
$-13.45M |
|
$1.21M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.54 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-15.50M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-95.80% |
|
-95.80% |
|
-34.32% |
|
-95.80% |
|
$0.11 |
|
$-0.24 |
|
$-0.24 |
|